Wealth Enhancement Advisory Services LLC Increases Holdings in Bristol Myers Squibb Company $BMY

Wealth Enhancement Advisory Services LLC grew its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 26.3% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,533,355 shares of the biopharmaceutical company’s stock after buying an additional 318,898 shares during the quarter. Wealth Enhancement Advisory Services LLC’s holdings in Bristol Myers Squibb were worth $84,075,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently modified their holdings of BMY. Darwin Wealth Management LLC purchased a new position in shares of Bristol Myers Squibb during the 2nd quarter valued at $25,000. Harbor Capital Advisors Inc. raised its holdings in Bristol Myers Squibb by 107.2% during the third quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 313 shares during the period. KERR FINANCIAL PLANNING Corp purchased a new position in shares of Bristol Myers Squibb in the third quarter valued at about $35,000. JPL Wealth Management LLC purchased a new position in shares of Bristol Myers Squibb in the third quarter valued at about $36,000. Finally, Total Investment Management Inc. bought a new position in shares of Bristol Myers Squibb in the second quarter worth about $38,000. Institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Price Performance

NYSE:BMY opened at $57.42 on Monday. The firm has a market capitalization of $116.93 billion, a price-to-earnings ratio of 16.64, a PEG ratio of 0.16 and a beta of 0.26. The company has a debt-to-equity ratio of 2.32, a current ratio of 1.26 and a quick ratio of 1.14. The business has a 50 day simple moving average of $58.60 and a 200-day simple moving average of $51.87. Bristol Myers Squibb Company has a 1 year low of $42.52 and a 1 year high of $62.89.

Bristol Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share for the quarter, missing the consensus estimate of $1.65 by ($0.39). The company had revenue of $12.50 billion for the quarter, compared to the consensus estimate of $12.24 billion. Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The business’s revenue for the quarter was up 1.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.67 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Equities analysts forecast that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, May 1st. Stockholders of record on Thursday, April 2nd will be issued a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 4.4%. The ex-dividend date is Thursday, April 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is 73.04%.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the company. Citigroup lifted their target price on Bristol Myers Squibb from $60.00 to $64.00 and gave the company a “neutral” rating in a research note on Friday, February 6th. Barclays started coverage on shares of Bristol Myers Squibb in a report on Thursday, February 19th. They set an “overweight” rating and a $75.00 price objective for the company. Scotiabank reissued a “sector perform” rating and issued a $60.00 target price (up from $53.00) on shares of Bristol Myers Squibb in a report on Friday, January 9th. The Goldman Sachs Group restated a “neutral” rating and issued a $57.00 price target (up from $51.00) on shares of Bristol Myers Squibb in a research report on Tuesday, December 2nd. Finally, Guggenheim reiterated a “buy” rating and set a $72.00 price objective (up from $62.00) on shares of Bristol Myers Squibb in a research report on Friday, February 6th. Nine investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Bristol Myers Squibb presently has a consensus rating of “Hold” and an average target price of $61.41.

Key Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: U.S. and EMA approvals expanded Opdivo’s use into frontline Stage III/IV classical Hodgkin’s lymphoma for patients 12+, strengthening BMY’s oncology franchise and near‑term revenue potential. Bristol Myers Squibb Transforms the Classical Hodgkin Lymphoma Treatment Paradigm with Expanded U.S. and EMA Approvals for Opdivo US FDA approves Bristol Myers Squibb’s cancer drug for Hodgkin’s lymphoma
• Positive Sentiment: Sotyktu (BMY) received a label expansion into psoriatic arthritis, broadening BMY’s immunology franchise and helping offset pressure from legacy oncology and cardiovascular patent cliffs. Will the Recent Label Expansion of BMY’s Sotyktu Boost Its Prospects?
• Positive Sentiment: BMY advanced its protein‑degradation program: first‑in‑human dosing of BMS‑986506 for clear cell renal cell carcinoma triggered a $10M milestone to Evotec, signaling pipeline progress and potential long‑term upside if early data read out well. Evotec Receives $10 M Milestone from Bristol Myers Squibb Protein Degradation Collaboration
• Neutral Sentiment: HSBC nudged its price target to $60, a modest analyst upgrade that signals some confidence but is unlikely to drive large near‑term moves on its own. HSBC Boosts Bristol Myers Squibb (NYSE:BMY) Price Target to $60.00
• Neutral Sentiment: BMY scheduled Q1 2026 results for April 30 — a near‑term event that could reprice the stock depending on revenue and EPS versus guidance/expectations. Bristol Myers Squibb to Report Results for First Quarter 2026 on April 30, 2026
• Neutral Sentiment: Coverage pieces (Schaeffer, Zacks) have highlighted BMY as a recommended pick or trending ticker, which can lift interest but may already be priced in. Top Stock Picks of 2026: Bristol-Myers Squibb Here is What to Know Beyond Why Bristol Myers Squibb Company (BMY) is a Trending Stock
• Negative Sentiment: Technical weakness flagged by a potential “death cross” (50‑day moving average crossing below 200‑day) can prompt selling by trend‑followers and contributed to the down‑pressure. These 3 Stocks Trigger Bearish Signals but 2 Offer Hidden Opportunity

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.